The inhibition of AR expression and signalling suggest a mechanism by which 25-OCH3-PPD could reduce the risk for development of prostate cancer and function in the treatment of both androgen-dependent and androgen-independent prostate cancer. Here, AR is linked to prostate carcinoma.